主页 > 生命科学 >
【drug-news】皮肤癌药物出现曙光
Skin Cancer Drug Said to Show Promise
By MARIA CHENG – 1 hour ago
BARCELONA, Spain (AP) — A very early test of an experimental drug seemed to slow the spread of advanced deadly skin cancer in a small study, the drug's U.S. developer reported in preliminary findings Wednesday.
Synta Pharmaceuticals Corp. of Lexington, Mass., reported that patients with advanced melanoma who got the drug survived an average of 3.7 months without new cancer lesions, compared to 1.8 months for those who got the standard treatment.
The treatment, given as a pill, is so early in development it doesn't have a name. It must pass muster in much more rigorous testing before the company seeks U.S. approval.
Synta's drug is one of several in development by other companies trying a new strategy against cancer — killing tumor cells by overloading them with oxygen.
"We are taking advantage of the Achilles heel of cancer cells," said Dr. Anthony Williams, vice president of clinical research at Synta Pharmaceuticals.
The drug has no effect on normal cells, which can adjust to higher levels of oxygen that cause cancer cells to self-destruct.
Doctors who heard the results at the European Cancer Organization meeting were heartened but said further study is needed.
"This could have a profound effect on patients," said Dr. Alex Eggermont, president-elect of the European Cancer Organization and a surgical oncology professor at Erasmus University in Rotterdam, Netherlands. Eggermont was not connected with the study.
The study followed 81 patients with advanced melanoma for about two years. Twenty-eight received the standard chemotherapy drug paclitaxel and lived an average of 1.8 months with no new lesions, while 53 got paclitaxel plus the new drug and survived an average of 3.7 months with no new lesions.
Less than 5 percent of patients taking the new pill suffered serious side effects, such as a temporary drop in white blood cells, back pain and fatigue.
There are very few drugs available for people with advanced melanoma, which kills 70 percent of patients within one year. Globally, about 160,000 people have it.
The company plans a bigger study with more than 600 patients at 150 cancer centers worldwide. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Skin Cancer Drug Said to Show Promise
By MARIA CHENG – 1 hour ago
皮肤癌药物出现曙光
MARIA CHENG
BARCELONA, Spain (AP) — A very early test of an experimental drug seemed to slow the spread of advanced deadly skin cancer in a small study, the drug's U.S. developer reported in preliminary findings Wednesday.
西班牙，巴塞罗那（AP）周三，美国药物研发者在其前期试验报道说发现一种新药似乎可以降低高度恶性肿瘤细胞的扩散速度。
Synta Pharmaceuticals Corp. of Lexington, Mass., reported that patients with advanced melanoma who got the drug survived an average of 3.7 months without new cancer lesions, compared to 1.8 months for those who got the standard treatment.
Synta制药公司报道说对比传统治疗恶性黑色素瘤病人的药物平均存活1.8个月而言，这种新药可以使病人平均生存3.7个月，且没有新的肿瘤发生。
The treatment, given as a pill, is so early in development it doesn't have a name. It must pass muster in much more rigorous testing before the company seeks U.S. approval.
这种药片形式的新药目前尚处在研发的初期阶段，以至于还没有被命名。在获取美国的批准之前它还必须进行更大范围的试验。
Synta's drug is one of several in development by other companies trying a new strategy against cancer — killing tumor cells by overloading them with oxygen.
Synta公司是采用新的抗肿瘤机制的公司之一，这种新的抗肿瘤机制是通过使肿瘤细胞超负荷氧而达到杀伤肿瘤细胞的作用，
"We are taking advantage of the Achilles heel of cancer cells," said Dr. Anthony Williams, vice president of clinical research at Synta Pharmaceuticals.
“我们利用肿瘤细胞的阿喀琉斯小刺来抗肿瘤”Synta制药公司的副主席Anthony Williams博士如是说。
The drug has no effect on normal cells, which can adjust to higher levels of oxygen that cause cancer cells to self-destruct.
这种药物对正常细胞没有作用，然而可以调节肿瘤细胞的氧负荷达到较高的水平从而导致肿瘤细胞自我毁灭。
Doctors who heard the results at the European Cancer Organization meeting were heartened but said further study is needed.
在欧洲肿瘤组织会议上听到这个研究结果的医生们很受鼓舞，但是表示需要更进一步的研究。
"This could have a profound effect on patients," said Dr. Alex Eggermont, president-elect of the European Cancer Organization and a surgical oncology professor at Erasmus University in Rotterdam, Netherlands. Eggermont was not connected with the study.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-22 18:41
医学,生命科学网